Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 5000 participants.

Also called NCT02762851

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02762851
Other papers using this trial's data
  • Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial The Lancet. Global health, 2022-12 DOI, PubMed 36400089 PubMed links an erratum for this paper. Erratum: PMID 36462511

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Cameroon, China, India, Kenya, Lebanon, Mozambique, Nigeria, Philippines, Saudi Arabia, Sudan, Uganda, United Arab Emirates, Zambia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02762851. Randomized; quadruple masking; primary purpose treatment. Start 2016-06 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)
Acronym
RCT-IVVE
Condition
Heart Failure
Condition
Influenza
Intervention (Other)
Sterile saline
Intervention (Drug)
inactivated trivalent influenza vaccine
Lead sponsor
McMaster University (class: other)

Record details

Record id
cardio:ct-nct02762851
Content hash
5afcd30ab39d35d5fad78d8ce8db3e052ff82fdaf16bc75cf0ff1b096c39ecfb